Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer
Conclusions: Our findings indicate that PPS is highly associated with OS in second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer, while the association between PFS and OS is moderate. We recommend using OS as primary endpoint for clinical trial of ovarian cancer, however PFS is still an optional endpoint.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Mototsugu Shimokawa, Takahiro Kogawa, Takako Shimada, Toshiaki Saito, Hozumi Kumagai, Masafumi Ohki, Tsunehisa Kaku Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Epithelial Cancer | Ovarian Cancer | Ovaries